Certa plans pivotal scleroderma trial after Phase II data readout

Certa plans to discuss the pivotal trial design and associated development plans with the US Food and Drug Administration (FDA) in early 2024. The company will also seek complementary scientific advice from the European Medicines Agency (EMA) in mid-2024.